Work with thought leaders and academic experts in general pharmacology toxicology pharmaceutics

Companies can greatly benefit from collaborating with experts in General Pharmacology, Toxicology, and Pharmaceutics. These experts can provide valuable insights and expertise in drug development, toxicology studies, regulatory compliance, and more. By working with them, companies can enhance their research capabilities, develop innovative drugs, ensure the safety and efficacy of their products, and navigate complex regulatory processes. Additionally, academic researchers in this field can contribute to scientific publications, present at conferences, and establish collaborations with other industry experts. Overall, partnering with General Pharmacology, Toxicology, and Pharmaceutics experts can accelerate the success and growth of companies in the pharmaceutical and biotechnology industries.

Experts on NotedSource with backgrounds in general pharmacology toxicology pharmaceutics include Luke Connelly, Samiul Amin, Dr. Susanne Ressl, and Paul Schrater.

Luke Connelly

Professor of Health Economics, The University of Queensland, CBEH
Most Relevant Research Interests
Other Research Interests (53)
Health economics
insurance
Public Health, Environmental and Occupational Health
Safety, Risk, Reliability and Quality
Human Factors and Ergonomics
And 48 more
About
Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.

Samiul Amin

Professor of Practice at University of Miami Professor of Practice and Director ECAP at University of Miami with expertise in Formulation Design, Rheology, Biosurfactants, Biopolymers and Materials Science.
Most Relevant Research Interests
Other Research Interests (60)
Complex Fluids
Rheology
Microrheology
Protein Aggregation
Colloid and Surface Chemistry
And 55 more
About
With over 22 years of industry and academic experience in SoftMatter, colloids, and complex fluids, I am a Professor of Practice and Director of the Engineering Corporate Affiliate Program (ECAP) at the University of Miami. My mission is to bridge the gap between engineering education/research and industry needs, and to foster a culture of creativity, innovation, and entrepreneurship among students and faculty. I am also co-founder of FastFormulator a Formulation Design Lab developing novel sustainable formulations for a wide range of industries utilizing an integrated approach of High THroughput FOrmulation Automation/Advanced CHaracterization/AI-ML and based on deep colloid science/complex fluids insights. <br> As a leading researcher and consultant in formulation design and performance optimization of consumer, cosmetic, biopharmaceutical, and homecare products, I collaborate with multiple global companies and organizations to develop novel and sustainable solutions based on high throughput formulation, AI/ML, advanced characterization and novel sustainable materials. I also teach courses in polymers, surfactants, emulsions, rheology, tribology, and innovation management, and chair international conferences in my field of expertise. I am passionate about advancing the science and engineering of complex fluids and cosmetics, and sharing my knowledge and insights with the next generation of engineers and innovators.

Example general pharmacology toxicology pharmaceutics projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on general pharmacology toxicology pharmaceutics?

Preclinical Drug Development

An academic researcher in General Pharmacology, Toxicology, and Pharmaceutics can collaborate with a pharmaceutical company to conduct preclinical studies on potential drug candidates. This collaboration can help identify the safety and efficacy of the drugs, optimize dosage regimens, and assess potential toxicities.

Toxicology Assessment

Companies can collaborate with experts in General Pharmacology, Toxicology, and Pharmaceutics to assess the toxicological effects of their products. This collaboration can help ensure the safety of drugs, cosmetics, chemicals, and other substances before they are introduced to the market.

Regulatory Compliance

Academic researchers in General Pharmacology, Toxicology, and Pharmaceutics can provide guidance and expertise in navigating complex regulatory processes. They can assist companies in preparing regulatory submissions, conducting studies to meet regulatory requirements, and ensuring compliance with applicable laws and regulations.

Drug Formulation and Delivery

Collaborating with experts in General Pharmacology, Toxicology, and Pharmaceutics can help companies in developing innovative drug formulations and delivery systems. These experts can provide insights into optimizing drug stability, bioavailability, and targeting specific tissues or cells.

Drug Safety Evaluation

Companies can benefit from the expertise of General Pharmacology, Toxicology, and Pharmaceutics researchers in evaluating the safety of their drugs. These experts can design and conduct studies to assess potential adverse effects, identify drug interactions, and evaluate the overall safety profile of the drugs.